Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 open-label randomized study of pegvaliase in adolescents with phenylketonuria
2021-005058-27Phase 3Active
- Sponsor
- BioMarin Pharmaceutical Inc.
- Start
- Mar 2022
- Modality
- Replacement Enzymes → Therapeutic Enzymes → Recombinant Proteins and Enzymes, PEGylated Peptides → Modified Peptides → Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of pegvaliase in phenylketonuria (PKU) (2 arms), sponsored by BioMarin Pharmaceutical Inc. Primary endpoint: Safety. Started Mar 2022; status: active.
02
Drugs
pegvaliase
03
Conditions
phenylketonuria (PKU)
Beyond the preview
Go deeper on 2021-005058-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-005058-27.